| Literature DB >> 35149701 |
Henryk Liszka1,2,3, Małgorzata Zając4,5, Artur Gądek6,7.
Abstract
The aim of this study is to assess whether administration of gabapentin and methylprednisolone as "pre-emptive analgesia" in a group of patients above 65 years of age would be effective in complex pain management therapy following total knee arthroplasty (TKA). One hundred seventy patients above 65 years were qualified for the study, with exclusion of 10 patients due to clinical circumstances. One hundred sixty patients were randomly double-blinded into two groups: the study group (80 patients) and the control group (80 patients). The study group received as "pre-emptive" analgesia a single dose of 300 mg oral (PO) gabapentin and 125 mg intravenous (IV) methylprednisolone, while the control received a placebo. All patients received opioid and non-opioid analgesic agents perioperatively calculated for 1 kg of total body weight. We measured (1) pain intensity level at rest (numerical rating scale, NRS), (2) life parameters, (3) levels of inflammatory markers (leukocytosis, C reactive protein CRP), and (4) all complications. Following administration of gabapentin and methylprednisolone as "pre-emptive" analgesia, the NRS score at rest was calculated at 6, 12 (p < 0.000001), 18 (p < 0.00004) and 24 (p = 0.005569) h postoperatively. Methylprednisolone with gabapentin significantly decreased the dose of parenteral opioid preparations (p = 0.000006). The duration time of analgesia was significantly longer in study group (p < 0.000001), with CRP values lower on all postoperative days (1, 2 days-p < 0.00001, 3 days-p = 0.00538), and leukocytosis on day 2 (p < 0.0086) and 3 (p < 0.00042). No infectious complications were observed in the first postoperative days; in the control group, one patient manifested transient ischemic attack (TIA). The use of gabapentin and methylprednisolone as a single dose decreased the level of postoperative pain on the day of surgery, the dose of opioid analgesic preparations, and the level of inflammatory parameters without infectious processes.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35149701 PMCID: PMC8837623 DOI: 10.1038/s41598-022-05423-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1A schematic diagram showing the CONSORT flowchart. Patient selection and randomization methylprednisolone + gabapentin vs placebo as pre-emptive analgesia TKA (total knee arthroplasty).
General data describing the analyzed elderly patients (over 65 years old) divided into the study group (M) and the controls (K).
| Data | Group (M) | Group (K) | p-value |
|---|---|---|---|
| n | 80 | 80 | |
| Age (years) | 73.5 ± 7.47 | 71.36 ± 5.23 | 0.21 |
| Mean hospitalization time (days) | 3.98 ± 0.92 | 5.81 ± 1.45 | 0.010 |
| Mean postoperative hospitalization time (days) | 3.01 ± 0.96 | 4.87 ± 1.15 | 0.0113 |
| Postoperative MAP (mmHg) | 96.39 ± 8.23 | 98.87 ± 10.99 | 0.328 |
| Postoperative pulse (x/min) | 68.75 ± 15.08 | 77.78 ± 21.50 | 0.0093 |
| Postoperative Sp02 (%) | 98.17 ± 0.98 | 98.60 ± 0.70 | 0.053 |
| Wound drainage (ml) | 353.57 ± 126.14 | 325.75 ± 105.41 | 0.351 |
MAP mean arterial pressure.
Distribution of comorbidities and anesthesia in the analyzed patients aged above 65 years old divided into the study group (M) and the controls (K).
| Data | Group M | Group K | p-value | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| n | 80 | 100.00 | 80 | 100.00 | |
| Hypertension arterial | 80 | 100.00 | 80 | 100.00 | |
| Atrial fibrillation, arrhytmia supraventricular | 9 | 11.25 | 9 | 11.25 | |
| IHD, myocardial infarction in anamnesis | 8 | 10 | 9 | 11.25 | 0.564 |
| COPD grade III | 6 | 7.5 | 5 | 6.25 | 0.789 |
| TIA in anamnesis | 6 | 7.5 | 5 | 6.25 | 0.621 |
| Cerebral tumor in anamnesis | 1 | 1.25 | 2 | 2.5 | 0.356 |
| Regional anesthesia | 80 | 100.00 | 80 | 100.00 | |
| Femoral nerve block-analgesia | 80 | 100.00 | 80 | 100.00 | |
| ASA II | 66 | 82.5 | 60 | 75 | 0.326 |
| ASA III | 14 | 17.5 | 20 | 25 | 0.129 |
| POSSUM physiological (points) | 17.42 ± 3.28 | 18.06 ± 4.45 | 0.537 | ||
| POSSUM morbidity (%) | 26.22 ± 12.91 | 26.54 ± 15.13 | 0.029 | ||
| POSSUM mortality (%) | 4.38 ± 3.55 | 4.94 ± 3.16 | 0.513 | ||
IHD ischaemic heart disease, COPD chronic obstructive pulmonary disease, TIA transient ischaemic attack, ASA American Society of Anesthesiology Score, POSSUM physiological and operative severity score for the enumeration of morbidity and mortality.
Figure 2Correlation parameters between group M and K: NRS score pain 6, 12, 18 h (p < 0.00001), POSSUM morbidity (p = 0.029), nerve block—time painlessness (p < 0.000001).
Figure 4NRS level (points) at rest at time points at 6, 12, 18 and 24 h postoperatively in the analysed patients above 65 years of age divided into the study (M) and control (K) groups.
Figure 5Dose of oxycodone hydrochloride in mg/kg body weight, paracetamol in mg/kg body weight, metamizole in g/kg body weight and time of postoperative analgesia in hours (h) not requiring administration of an analgesic agent in the analyzed patients above 65 years old divided into the study (M) and control (K) groups on day 0.
Figure 3Linear correlation r-Pearson NRS points day 0 and oxycodone hydrochloride mg/kg body mass group K.
Leukocytosis CRP and glucose levels in the analyzed patients aged above 65 years old divided into the study (M) and control (K) groups.
| Data | Group (M) | Group (K) | OR | − 95 CI | p-value |
|---|---|---|---|---|---|
| n | 80 | 80 | |||
| Initial blood leukocytosis level (× 103/µl) | 6.82 ± 1.38 | 6.91 ± 1.88 | − 0.083 | − 0.94/0.77 | 0.846 |
| Initial blood leukocytosis level—day 0 (× 103/µl) | 11.63 ± 2.52 | 10.92 ± 2.50 | 0.714 | − 0.57/2.00 | 0.272 |
| Blood leukocytosis level—day 1 (× 103/µl) | 13.78 ± 3.53 | 11.83 ± 3.35 | 1.94 | 0.17/3.71 | 0.031 |
| Blood leukocytosis level—day 2 (× 103/µl) | 10.08 ± 2.48 | 11.96 ± 2.85 | − 1.88 | − 3.26/− 0.49 | 0.0086 |
| Blood leukocytosis level—day 3 (× 103/µl) | 8.24 ± 1.85 | 10.96 ± 2.93 | − 2.71 | − 4.16/− 1.27 | 0.00042 |
| Initial blood CRP level (mg/l) | 3.09 ± 3.33 | 2.69 ± 1.55 | 0.39 | − 0.90/1.69 | 0.543 |
| Blood CRP level—day 0 (mg/l) | 8.91 ± 12.07 | 18.33 ± 12.69 | − 9.42 | − 15.8/− 3.03 | 0.0045 |
| Blood CRP level—day 1 (mg/l) | 28.39 ± 21.57 | 61.06 ± 24.57 | − 32.66 | − 44.61/− 20.71 | < 0.000001 |
| Blood CRP level—day 2 (mg/l) | 53.92 ± 41.89 | 105.52 ± 32.68 | − 51.60 | − 70.71/− 32.48 | < 0.000001 |
| Blood CRP level—day 3 (mg/l) | 53.85 ± 51.04 | 97.12 ± 36.12 | − 43.27 | − 66.83/− 19.72 | 0.000538 |
| Wound drainage fluid CRP level (mg/l) | 8.09 ± 10.61 | 5.29 ± 4.37 | 2.79 | − 1.24/6.84 | 0.171 |
| Initial blood glucose level (mmol/l) | 6.13 ± 1.13 | 5.79 ± 1.10 | 0.33 | − 0.23/0.91 | 0.247 |
| Blood glucose level—day 0 (mmol/l) | 7.63 ± 0.90 | 7.66 ± 1.05 | − 0.02 | − 0.53/0.48 | 0.910 |
| Blood glucose level—day 1 (mmol/l) | 7.70 ± 0.83 | 7.94 ± 0.90 | − 0.23 | − 0.68/0.21 | 0.295 |
| Blood glucose level—day 2 (mmol/l) | 6.82 ± 0.62 | 7.14 ± 0.69 | − 0.31 | − 0.66/0.02 | 0.068 |
| Blood glucose level—day 3 (mmol/l) | 5.79 ± 0.58 | 5.88 ± 0.53 | − 0.09 | − 0.38/0.19 | 0.505 |
CRP C reactive protein, OR odds ratio, CI confidence interval.